A glycoprotein called SuPAR is released when there is an infection or inflammation. It is a urokinase-type plasminogen activator receptor that is serum soluble. Urokinase-type plasminogen activator (uPA), which is secreted by macrophages and polymorphonuclear neutrophils (PMN), attaches to the membrane’s uPAR (urokinase-type plasminogen activator receptor). The suPAR is produced by cleavage from the uPAR. In patients with cancer, infectious disorders, and inflammatory diseases, SuPAR has the ability to either cause or modify a number of diseases (including HIV infections, tuberculosis, liver fibrosis, and inflammatory bowel disease). SuPAR can transform plasminogen into plasmin during cellular invasion, which breaks down fibrin, activates matrix metalloproteases, and facilitates the proteolysis of extracellular matrix proteins. SuPAR regulates the functions of integrins, including triggering intracellular signalling, monocyte chemotaxis, cell adhesion, and proliferation. According to multiple research, SuPAR level is an important marker in patients with different diseases and has been connected to a worse result in a number of infectious and non-infectious conditions. In order to characterise clinical phenotypes, aid in diagnosis, and monitor the efficacy of both tried-and-true and cutting-edge therapeutic methods, lung disease biomarkers are essential. In this review, we look into suPAR’s potential as a universal marker for the diagnosis, prognosis, and therapeutic monitoring of lung diseases.

Author(s) Details:

Ummugulsum Can,
Department of Biochemistry, Konya City Hospital, Konya, Turkey.

Sadinaz Akdu,
Department of Biochemistry, Muğla, Fethiye State Hospital, Turkey.

Please see the link here: https://stm.bookpi.org/CODHR-V3/article/view/7897

Keywords: Therapeutic monitoring, phenotypes, plasminogen activator receptor, plasminogen activator